CNBC Investment News
Expert Analysis, Investment Tools, Stock Screeners, and Financial Strategy Information.
Updated: 8 hours 46 min ago
Shareholders went nuts when jeweler Signet paid $1.4 billion for Zales in 2014. Now it's unraveling.
Bill Ackman blames Valeant implosion for the "worst period of performance" of his investment career.
CNBC Pro highlights the top-performing stocks this week and analyzes whether the good times will continue.
Telsey Advisory Group lowers its rating for Viacom, citing the prospects of a credit rating downgrade or dividend cut.
But St. Louis Fed President James Bullard wouldn't be firm, saying he would like to raise rates on good economic news.
Stellar inflows into fixed income this week has caused one investment bank to warn of a "bond shock" in the coming months.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
Zev Spiro of Orips Research tells CNBC why he believes oil could rise above $70.
Names on the move ahead of the open.
This month's moderate rebound in the oil price is likely to cool next year, according to analysts at Bank of America Merrill Lynch.
Jim Cramer says executive embarrassment and presidential candidate tweets won’t solve the EpiPen problem.
Jim Cramer says it's time for Apple to put its massive $231 billion cash hoard to work, and buy this company.
Shares of two jewelers were on the move Thursday after reporting quarterly earnings.
Shares of St. Jude Medical briefly fell more than 8 percent Thursday after Muddy Waters Capital announced the firm is short the stock.
Shares of Workday climbed 7 percent after the enterprise software company reported an increase in subscriber revenue.
Dollar Tree and Dollar General reported same-store sales results that fell short of Wall Street's expectations.
Shares of Mylan held slightly lower in afternoon trade, giving up earlier gains of more than 4 percent.
Europe's pursuit of companies like Apple for under-paid taxes highlights a major problem with few prospects for a global solution.
As political pressure appears to mount on biotech stocks, some technicians say a bounce may be coming.
Did you predict that oil would bounce in 2016? Nice! Did you attempt to cash in by buying the biggest oil ETF? Oops.